Dianthus Therapeutics Prices $625M Public Offering at $81
ArchivedVerified|4 articles|2 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Dianthus Therapeutics set the share price at $81 for its public offering on March 11, 2026.
- •The total amount raised from the offering was $625 million, exceeding the initial target.
- •CEO Garcia sold $10 million worth of Dianthus shares on March 14, 2026.
- •Xenon Pharmaceuticals also completed an upsized $650 million offering at $57 per share on March 11, 2026.
What Could Happen If...
- ▸If Dianthus Therapeutics successfully deploys the $625 million capital the company could accelerate its drug development programs, potentially advancing clinical trials and increasing shareholder value.
Market Exposure
StocksDianthus Therapeutics common stockIncreased Volatility
The large share offering and insider sale may cause fluctuations in Dianthus's stock price as investors react to changes in share supply and insider activity.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Instruments
Organizations
Source Coverage
FINANCE
4 articles
More coverage on this story
- More on Dianthus Therapeutics common stock
- More on Dianthus Therapeutics
Signals
Single-block coverageLow source diversity
Related Events
▸Spyre Therapeutics Launches $300M Stock Offering to Fund GrowthArchived▸Amer Sports prices 20.6M share public offering at $36.40Archived▸Coherus Oncology prices stock offering to raise $50.1MArchived▸Clean Harbors Director Welch Sells $204,802 in Company StockArchived▸Generate Biomedicines Files for $425 Million Nasdaq IPOArchived